Abstract: The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions.

Abstract: The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions.

Abstract: The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions.

Abstract: The present application relates methods and uses of oral diamidines or pharmaceutically acceptable salts thereof for the treatment of liver diseases or conditions.

Abstract: The invention relates to the discovery that the dibenzodiazepinone analogues have growth inhibiting activities on tumorigenic cells that are driven by expression of RAS or mutated RAS. Thus the invention includes methods for inhibiting the activity of RAS using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer cell using dibenzodiazepinone analogues; methods for inhibiting the growth of a RAS driven cancer using dibenzodiazepinone analogues; and methods for treating a subject having a RAS driven cancer using dibenzodiazepinone analogues.

Abstract: The invention relates to a method for evaluating a chemotherapeutic potential of a candidate molecule. In evaluating the candidate molecule, the candidate molecule is tested for its ability to inhibit the in vitro growth of a cancer cell; to bind a cellular receptor produced by a cancer cell, wherein said receptor, such as a peripheral benzodiazepine receptor, is produced in a greater amount by said cancer cell than by a normal cell; and to inhibit the activity of at least one protein member of the MAPK pathway. The invention further relates to dibenzodiazepinone analogues and derivatives thereof.

Abstract: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I.

Abstract: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I.

Abstract: A composition comprising a protein having an inhibitory activity for a serine protease and, in particular, for a serine elastase, the protein having a molecular weight of about 46 kDa in a deglycosylated form, and having a molecular weight of about 54 kDa when isolated in a glycosylated form is provided. Methods of using the protein in treatments of diseases where inhibition of a serine protease and, in particular, of a serine elastase is effective are provided as well as compositions, reagents, and kits related thereto.

Abstract: Low molecular weight components extracted from shark cartilage and complexes made of copper with amino acid or dipeptide units or analogs thereof are disclosed. Methods are disclosed for the inhibition of angiogenesis (neovascularization) in an animal through the administration of these complexes, which results in treating angiogenesis-dependent diseases.

Abstract: Cloned genes which code for the D.sub.1 dopamine receptor are disclosed. The receptors coded for by these clones bind dopamine ligands with the proper pharmacological profile and, when expressed in the cell membrane of a suitable host and so bound, stimulate adenylyl cyclase. Also disclosed are vectors comprising a cloned gene encoding a D.sub.1 -dopamine receptor, cells transformed with such vectors, and oligonucleotide probes capable of selectively hybridizing to DNA comprising a portion of a gene coding for a D.sub.1 -dopamine receptor. The cloned genes are useful for making proteins and cell membrane preparations which can be used to screen compounds for D.sub.1 -dopamine receptor binding activity, are useful in molecular biology, and are useful as diagnostic probes.